Introduction {#s0005}
============

Pulmonary alveolar microlithiasis (OMIM \[Online Mendelian Inheritance in Man\] 265100) is a rare disease characterized by diffuse alveolar deposition of microliths ([@bb0005]). PAM was first described by Malpighi in 1686 and named by Puhr in 1933 ([@bb0010]). Since then, more than 500 cases have been reported all over the world ([@bb0020]). Among these patients, about one-third of them are familial. One remarkable feature of PAM is the late onset of symptoms despite the fact that it causes diffuse lung lesions. This is probably also the main reason why PAM is often incidental to other clinical diagnosis ([@bb0020]).

SLC34A2 is a type IIb sodium phosphate co-transporter which primarily expresses in alveolar type II cells. It is also the only known sodium-dependent phosphate transporter expressed in the lung. This protein plays a key role in clearing phospholipids of the alveolar space through transporting the phosphorus ion into the alveolar type II cells ([@bb0025]). Mutations that cause SLC34A2 dysfunction or deficiency could therefore result in an accumulation of the local phosphate in lung parenchyma, which may represent the main mechanism associated with the microlith formation. In 2006, Corut et al. first identified a PAM locus on chromosome 4p15 by homozygosity mapping, and proposed that the mutation of the *SLC34A2* gene causes PAM ([@bb0030]). Huqun et al. employed a modified homozygosity mapping method and discovered homozygous exonic mutations on exon 8 of the *SLC34A2* gene in PAM patients they examined ([@bb0035]). Other studies from Turkey, Japan and China have also described multiple mutations of this gene in PAM patients ([@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065]). However, the functions of these mutated proteins were not analyzed because of the poor understanding of their structures. Here we not only identified the mutations that caused PAM in this patient, but also computationally predicted 3D structures of these mutants. Our study may provide a novel strategy to help diagnose patients who may potentially develop PAM; it may also be used to estimate the prognosis.

Methods {#s0010}
=======

Case report {#s0015}
-----------

A 43-year-old man from a non-inbred family was admitted to the hospital complaining of recurrent dyspnea for 1 year. The symptom started as mild chest tightness but deteriorated significantly within a year. He was healthy in the past and denied any history of medication. He had a history of smoking for 20 years with 20 cigarettes per day. His parents are not consanguineous, and he has a sister and a son. None of them complained of discomfort and their chest CT scans were normal.

Physical examination upon admission revealed apparent cyanosis of lips, venous varicose and slight bulb fingers. Crackle rales were heard in both lung fields. Laboratory tests revealed an increased level of hemoglobin (171 g/L) and a decreased level of PaO~2~ (49.3 mm Hg); the serum calcium concentration and the tumor index panel were within the normal range. Ultrasound cardiogram showed enlargement of the right ventricle with severe pulmonary arterial hypertension. The dilation function of the left ventricle was found declined. Spirometry exam showed severe restrictive ventilatory disturbances and a decreased diffusing capacity (vital capacity, 44.2% of predicted, forced expiratory volume in 1 s, 84.4% of predicted, carbon monoxide transfer factor-single breath, 42.0% of predicted). Bronchoalveolar lavage fluid (BALF) was milky with negative Rivalta test. Smear of BALF showed fine sand inside. Chest computed tomography (CT) scan showed a diffused infiltration of fine sand-stones in both lungs mainly in the upper fields, and with interstitial changes in lower lung fields ([Fig. 1](#f0005){ref-type="fig"}A--D). Trans-bronchial lung biopsy showed lamellar microliths deposited in alveolar spaces and the pleura ([Fig. 2](#f0010){ref-type="fig"}A, B). The diagnosis of PAM was therefore established based on the symptoms, thorax imaging and the biopsy.

Genetic analysis {#s0020}
----------------

Genomic DNA was extracted from peripheral blood of the patient and his relatives as we previously described ([@bb0070]). The study was approved by the Ethics Committee of the second affiliated hospital, Zhejiang University School of Medicine (Ethic No. 2011-7), with a written consent form obtained from the subjects. Using the online software Primer3, 12 pairs of primers ([Table 1](#t0005){ref-type="table"}) were designed to amplify the coding exons and the intronic flanking sequences of the *SLC34A2* gene. The amplifications were performed in thermocyclers (PerkinElmer, Inc, Foster City, CA, USA), starting with an initial denaturation of 4 min at 95 °C followed by 12 cycles of 35 second denaturation and 35 second annealing at 60 °C (0.5 °C decrease in each cycle), and 40 second extension at 72 °C. DNA sequencing was then performed in an ABI 3100 Genetic analyzer (Applied Biosystems, Invitrogen, Shanghai). All identified disease-associated variants were examined for their presence in controls (100 healthy volunteers/200 chromosomes).

Computational prediction of 3D structures of the mutated proteins {#s0025}
-----------------------------------------------------------------

The functional impairment of the mutated proteins was evaluated computationally using web-based software programs. The bioinformation includes the hydrophobicity and the trans-membrane topological structure. ProtScale ([*http://ca.expasy.org/tools/protscale.htm*l](http://ca.expasy.org/tools/protscale.html){#ir0015}) was used to analyze the hydrophobicity; SOPMA from Centre National de la Recherche Scientifique (CNRS) was used to evaluate the secondary structure; and SMART ([*http://smart.embl-heidelberg.de*](http://smart.embl-heidelberg.de){#ir0020}) was used to assess the trans-membrane domains. The 3D structures of the wild-type SLC34A2 and the mutants were predicted by protein folding recognition with 3D-pssm (Phyre Version0.2). The initial 3D structures were acquired *via modeler 9.11,* and the structure optimization and the dynamic simulation were done via the software *Material Studio* (minimizer and dynamics program) ([@bb0075], [@bb0080]). Procheck was used to verify the quality of the predicted protein structures ([@bb0085]).

Results {#s0030}
=======

Identification of a compound heterozygous mutation {#s0035}
--------------------------------------------------

A compound heterozygous mutation was identified in the patient. One is c.1363T \> C (p. Y455H) in exon 12, which is also seen in his mother, son and sister (a, b, d and e of [Fig. 3](#f0015){ref-type="fig"}A). The other is c.910A \> T (p.K304X) in exon 8, which was also seen in his father (a and c of [Fig. 3](#f0015){ref-type="fig"}B). Analysis of 100 healthy volunteers did not show these mutations (f of [Fig. 3](#f0015){ref-type="fig"}A and B). Based on these findings, we created a pedigree for this family ([Fig. 3](#f0015){ref-type="fig"}C). It is clear that this patient carries a compound heterozygous mutation.

Computational prediction of 3D structures of the mutated proteins {#s0040}
-----------------------------------------------------------------

Because functional examination of mutated proteins in a biological system is time-consuming and expensive, and the crystal structure of the SLC34A2 protein has not been solved, we reasoned that computational 3D structure prediction may provide useful information about the SLC34A2 protein and its mutants, which may also help assess the function of mutated proteins in a quicker and more efficient way. We found that the wild type SLC34A2 protein consists of 690 amino acids, which forms two domains and Domain II is the trans-membrane domain ([Fig. 4](#f0020){ref-type="fig"}A). The mutant caused by mutation c.910A \> T (p. K304X) in exon 8 leads to protein truncation, and the truncated protein has a length of only 303 amino acids ([Fig. 4](#f0020){ref-type="fig"}B). Overlapping of this truncated protein with the wild type showed that these two proteins share very few common functional regions ([Fig. 4](#f0020){ref-type="fig"}C). Mutation c.1363T \> C (p. Y455H) in exon 12 resulted in a point mutation of TAT (Tyrosine) to CAT (Histidine). Although this mutation did not lead to a length change of the protein ([Fig. 4](#f0020){ref-type="fig"}D), it caused an irregular coil formation in the trans-membrane domain, as well as in the domain I ([Fig. 4](#f0020){ref-type="fig"}E).

Discussion {#s0045}
==========

In this study, we identified a compound heterozygous mutation of the *SLC34A2* gene in a PAM patient, and computationally predicted 3D structures of the mutants.

Although the etiology of PAM was unclear, the incidence of the familial occurrence of the disease is high, ranging from about 30% to 50% of all the cases reported. PAM often affects horizontal siblings from inbred families, suggesting that this is an autosomal recessive disease ([@bb0090]). Despite the versatile mutation symbols, homozygous mutation is the most common genotype and protein truncation is the predominant form of these mutations. Our patient exhibited a mutation symbol that is completely different from previous reported cases. This compound heterozygous mutation resulted in the expression of two different mutated proteins. The mutation of c.910A \> T (p. K304X) in exon 8 leads to a premature termination in the C-terminal region, as been previously reported ([@bb0065], [@bb0095]). The mutation in exon 12 caused a point mutation, which has not been reported before. Further familial analysis revealed that the father carried the mutation of c.910A \> T (p. K304X) in exon 8, and the mother carried the mutation of c.1363T \> C (p. Y455H) in exon 12. Nevertheless, the clinical manifestation of this patient is similar to other patients with homozygous mutation, indicating that both mutations caused the functional loss of the protein.

The functions of the mutated SLC34A2 proteins are not well known. Among all those previous reports, only Hunqun et al. performed a functional study through an assay of phosphate uptake by Xenopus oocytes, which were engineered to express either wild type or mutated *SLC34A2* genes ([@bb0035]). However, this study did not provide information about functional regions of the wild type or mutated proteins. Furthermore, the technique of in vitro microinjection is time-consuming and costly, limiting its application in such versatile mutation symbols. In the present study, we took the advantage of the bioinformatic technology and predicted 3D structures of the proteins in a quicker and reliable way by using online softwares. In the predicted 3D structure image, the residual segments of the truncated mutant displayed little overlap with the wild type SLC34A2 protein, suggesting a significant functional change of this mutant. While the protein with the point mutation displayed a decent overlap with that of the wild type in the 3D image, the mutation from Tyrosine to Histidine results in a remarkable local structure change of the α helix, possibly because of the appearance of the positive charge at the residue 455. This result suggested that the amino acid (aa455) as well as the relevant domain is likely functionally important for the SLC34A2 protein.

PAM pathogenesis is characterized by an early onset and very slow development. Although full penetrance of genetic defect has been noticed in the development of PAM ([@bb0030]), non-genetic environmental factors seem to play an important role in the progression of this disease. Heavy smokers seem to have severer phenotype ([@bb0030]). Infection might also accelerate the progression. The symptoms of our patient progressed fast within one year, which might be attributable to his long history of heavy smoking. Although extra-pulmonary calcification has been reported in some patients with PAM ([@bb0100], [@bb0105]), the pathology of our patient is limited to the lung.

Another phenomenon worth mentioning is that patients with different races tend to exhibit distinct mutation sites. Mutation sites of patients from Turkey were often on multiple exons; those of Japanese patients were mainly on exons 7 and 8. However, mutation sites of Chinese patients were found on the exon 8 prior to this study. In our previous studies, we analyzed gene mutation sites in Chinese patients with PAM and postulated that exon 8 might be the main target for PAM screening in China. The current study further confirmed that exon 8 is the main mutation site, and in addition, exon 12 may represent another target that needs attention.

In conclusion, we have identified a compound heterozygous mutation of the *SLC34A2* gene in a non-inbred Chinese PAM patient. We also analyzed the functional regions of the wild type and two mutants of the *SLC34A2* gene for the first time through a computational 3D protein structure prediction. Together with our previous work ([@bb0070]), this study further suggested that exon 8 might be the main susceptibility loci of Chinese PAM patients. Identification of genetic mutations plus computational prediction of 3D structures of the mutants may represent a novel supporting diagnostic strategy for patients that are highly suspicious of developing PAM. And this strategy may also be used as a means to estimate prognosis for established PAM patients.
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![High-resolution computed tomography (CT) of chest. Axial CT image shows extensive micronodular opacity within the lung parenchyma; signs of fibrosis and interstitial thickening were also seen. (A) Upper lung, mediastinal window. (B) Lower lung, lung window. (C) Coronal multiplanar reformation images. (D) Transparency view of the lungs shows diffuse symmetric involvement of both lungs, with a predominant distribution of micromodular opacity in the upper lobes.](gr1){#f0005}

![H & E staining of transbronchial biopsy specimens. Deposition of concentrically laminated, partially calcified spheroid bodies in the visceral pleura (A) and alveolar space (A, B). (Black arrow, pleural microliths; blue arrows, alveolar microliths; magnifications, A, × 100; B, × 400).](gr2){#f0010}

![Genetic analysis and the pedigree structure of the family with PAM. (A) The mutation of c.1363T \> C (p. 455Y \> H) in exon 12 (sequences shown in this panel are corresponding reverse sequences). (B) The mutation of c.910A \> T (p. K304X) in exon 8.\
(a, The PAM patient; b, the mother of the patient; c, the father of the patient; d, the son of the patient; e, the sister of the patient; f, normal control). (C) Pedigree structure of the family. (Square symbols, men; circular symbols, women; filled symbols, PAM affected; dotted symbols, mutant carrier. The proband is marked by an arrow).](gr3){#f0015}

![Predicted 3D structure of wild type SLC34A2 and the two mutants. (A) Wild type SLC34A2, domain II is the transmembrane domain. (B) Truncated mutant caused by the mutation c.910A \> T (p.K304X) in exon 8. (C) Overlapping of the truncated protein with the wild type SLC34A2. (D) Mutated protein caused by the mutation c.1363T \> C(p. Y455H)in exon 12. (E) Overlapping of the wild type SLC34A2 with the mutant containing the point mutation.](gr4){#f0020}

###### 

Sequences of primers and length of the amplicons.

  -------------------------------------------------------------------
  Sequences of primers                      Length of the amplicons
  ----------------------------------------- -------------------------
  SLC34A2-1F: CCGTCGGAGCTTTTCTCTCGG\        477 bp
  SLC34A2-1R: GTCGATCGTAAGAGTGTAGCAGC       

  SLC34A2-2-3F: GTTGATGCTTTGCAACCAATGG\     500 bp
  SLC34A2-2-3R: TGATGACACCCACAGTGAACG       

  SLC34A2-4F: GCTCATTGCCAAACTTCTCAGG\       300 bp
  SLC34A2-4R: GCTGGAGAGGGCTTGCTGA           

  SLC34A2-5F: GGCCTTGGATGGAGACTTCTG\        302 bp
  SLC34A2-5R: TCCCACCCTCAGATAGACAGG         

  SLC34A2-6F: GGTAACTTTAGCCTGCCTCCAG\       270 bp
  SLC34A2-6R: GCATGTCATCTTTGGCTGGTT         

  SLC34A2-7F: GAGGGTGGCAGATGATACAGG\        357 bp
  SLC34A2-7R: TGTCAGCTCAGGTAGGGGATG         

  SLC34A2-8F: CCCTGGGTTTGTGTCCTAAATC\       243 bp
  SLC34A2-8R: CTTCCTTGAAGGCAAGATTTAGTT      

  SLC34A2-9F: CATTGCCTCCCATTCCCCACT\        241 bp
  SLC34A2-9R: AATAGGTCACCCCCAGACAAC         

  SLC34A2-10F: TAACAATCTGTAGCCGTGGTGG\      300 bp
  SLC34A2-10R: GAATCTAAAGGACCCCCACAC        

  SLC34A2-11-12F: TGTACAACCTCACCCCTAAGCC\   499 bp
  SLC34A2-11-12R: AGAGACCAGTTTGCAAGACCATG   

  SLC34A2-13-1F: TGTGATGCCTGCTAGCTTACCT\    492 bp
  SLC34A2-13-1R: CAGCAGCGCATCTGGAAGCAG      

  SLC34A2-13-2F: CTGCCGAAGAAACTCCAGAACT\    481 bp
  SLC34A2-13-2R: CCAAAGGGAATCGAGTTAGGTAG    
  -------------------------------------------------------------------
